stockportfolio.pro
Stocks / BLTE vs CGON
BLTE vs CGON
Belite Bio, Inc and CG Oncology, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Belite Bio, Inc (BLTE) | CG Oncology, Inc. (CGON) | |
|---|---|---|
| Market cap | $5.5B | $5.1B |
| Revenue (latest FY) | $0 | $4.04M |
| Net income (latest FY) | $-77.61M | $-161.00M |
| Revenue growth (5y CAGR) | — | 176.6% |
| Net margin | — | -3985.0% |
| Return on equity | -10.1% | -21.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BLTE — free Open CGON — freeFrequently asked questions
Which is bigger, BLTE or CGON?
Belite Bio, Inc is larger by market capitalization — $5.5B versus $5.1B.
Which grows faster, BLTE or CGON?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.